Clinical trial
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects…
NCT05672576 · Viatris Innovation GmbH, Industry · Active, not recruiting
Key facts
| NCT number | NCT05672576 |
|---|---|
| Title | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus |
| Official title | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy |
| Acronym | OPUS-2 |
| Lead sponsor | Viatris Innovation GmbH, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Erythematosus, Systemic |
| Intervention type | Drug |
| Interventions | Cenerimod, Placebo |
| Enrollment | 451 |
| Start date | Jun 26, 2023 |
| Primary completion | Oct 31, 2026 |
| Completion | May 1, 2027 |
| First posted | Jan 5, 2023 |
| Last update posted | Feb 9, 2026 |
| Countries | Chile, Czechia, Georgia, Germany, India, Malaysia, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: